Inositol hexanicotinate is a modified form of vitamin B3 (niacin) built so the body releases niacin slowly after absorption, which is why supplement labels often market it as “flush-free” niacin. The compound links six niacin molecules to a central inositol molecule, and once swallowed, it gets broken apart gradually in the bloodstream. Whether that slow release translates into the same cholesterol-lowering benefits as regular niacin is a question the clinical evidence has not settled neatly.
How the Molecule Is Built
Inositol hexanicotinate, sometimes abbreviated IHN, is technically the hexanicotinic acid ester of meso-inositol. That means a single inositol molecule sits at the core, and six molecules of nicotinic acid (the chemical name for niacin) are chemically bonded to it, one at each available position on the inositol ring. The result is a relatively large, stable molecule that behaves differently from free niacin when it enters your gut and bloodstream. You will also see it labeled as inositol hexaniacinate or inositol nicotinate on supplement packaging, and the older pharmaceutical brand name Hexopal refers to the same compound.
The design is intentional. Free niacin, when taken in large doses for cholesterol management, dumps into the bloodstream quickly and triggers an intense skin flush that many people find intolerable. By locking niacin into a larger molecular scaffold, IHN forces the body to do extra work before niacin becomes available. The hope is that this slower delivery softens the side effects while preserving the benefits.
How the Body Breaks It Down
When you take an IHN supplement, the compound appears to be absorbed at least partially intact rather than falling apart in the stomach. Once in the bloodstream, enzymes gradually clip the niacin molecules off the inositol backbone through a process called hydrolysis. This releases free nicotinic acid and free inositol into circulation over a longer window than you would get from swallowing plain niacin.
Lab studies have measured how fast this happens. When IHN was incubated in human plasma at body temperature, the parent compound disappeared with a half-life of roughly one hour, meaning half of it was broken down in that time. But the corresponding free niacin took nearly four hours to reach its halfway point of accumulation, suggesting a staged release rather than an all-at-once burst.1PubMed. Biotransformation and pharmacokinetics of inositol hexanicotinate in rats That mismatch between how fast IHN vanishes and how slowly niacin appears hints that intermediate breakdown products linger for a while before fully releasing their niacin payload.
This staged release is the pharmacological selling point. It also raises a practical problem: if niacin trickles out slowly enough to avoid flushing, it may also never reach the blood concentrations needed to shift your lipid levels. That tension runs through nearly every clinical debate about IHN.
Why Regular Niacin Causes Flushing
To understand why IHN is marketed the way it is, you need to know what niacin flush actually is. Within about 20 to 30 minutes of taking a therapeutic dose of plain niacin, many people experience intense warmth, redness, and tingling across the face, neck, and upper body. It can feel alarming, especially the first few times, and it is one of the main reasons people stop taking niacin even when it is working well for their cholesterol.
The flush happens because free niacin activates a specific receptor on immune cells in the skin called Langerhans cells. When niacin binds to this receptor, it triggers the release of prostaglandins that dilate the small blood vessels near the skin’s surface.2PubMed Central. The mechanism and mitigation of niacin-induced flushing The prostaglandins involved, primarily prostaglandin D2 and prostaglandin E2, act on receptors in the capillary walls to widen them, which is what creates the visible redness and the sensation of heat.3PubMed. Mechanism of action of niacin The flush is not dangerous, but it is uncomfortable enough that it has driven an entire category of “no-flush” supplements.
Because the flush is dose-dependent and linked to peak blood levels of free niacin, the logic behind IHN is straightforward: if the molecule releases niacin gradually instead of all at once, the peak concentration should stay below the threshold that triggers the prostaglandin cascade in skin cells. And on that narrow point, IHN does seem to deliver. Most users report little or no flushing at typical supplement doses. The question is what else gets lost alongside the flush.
The Cholesterol Evidence Is Genuinely Mixed
Free niacin, when taken at prescription-grade doses of one to three grams per day, has a well-documented track record of raising HDL cholesterol and lowering LDL cholesterol and triglycerides. It was one of the first drugs ever shown to improve lipid profiles, and for decades it was a standard tool in cardiovascular medicine. The natural assumption was that IHN, as a niacin delivery vehicle, would do the same thing minus the flush. The clinical data has not cooperated.
The most direct head-to-head comparison involved people with mild to moderate cholesterol problems assigned to either extended-release niacin, IHN, or placebo. The IHN group saw essentially no change in their lipids: total cholesterol dropped about one percent, LDL dropped about one percent, HDL went up about one percent, and triglycerides actually nudged up about two percent. None of those shifts were statistically significant, and the IHN results were indistinguishable from placebo.4Journal of Clinical Lipidology. Wax-matrix extended-release niacin vs inositol hexanicotinate: A comparison of wax-matrix, extended-release niacin to inositol hexanicotinate “no-flush” niacin in persons with mild to moderate dyslipidemia The researchers concluded bluntly that IHN appeared to be “virtually nonbioavailable” for the purpose of managing dyslipidemia. Extended-release niacin, by contrast, moved all the lipid markers in the expected direction.
That finding is hard to ignore, but it is not the entire picture. A separate study found a statistically significant rise in HDL cholesterol, from roughly 34 to 37 mg/dL, after twelve weeks of IHN therapy.5Circulation. Inositol Hexa Nicotinate is a Safe and Effective Alternative of Niacin for Treatment of Dyslipidemia An increase of about three points in HDL is modest in absolute terms, but it was consistent enough across participants to reach strong statistical significance. That result suggests IHN is not completely inert, at least for HDL. Still, a three-point HDL bump is far smaller than what prescription niacin routinely achieves, and it leaves the harder-to-move markers like LDL and triglycerides largely unaddressed.
So the honest read of the evidence is that IHN’s slow niacin release, while great for avoiding flushing, may genuinely limit how much free niacin reaches the bloodstream at any one time. The concentrations may simply never get high enough to activate the liver pathways that shift lipid production. If your primary goal is cholesterol management, the data leans strongly toward IHN being inadequate for that job at typical supplement doses.
Raynaud’s Disease and Peripheral Circulation
The cholesterol story tends to dominate online discussions of IHN, but the compound has a separate and somewhat more encouraging track record in treating Raynaud’s disease, a condition in which blood vessels in the fingers and toes overreact to cold or stress by constricting sharply. Episodes cause the affected digits to turn white or blue, go numb, and sometimes become painful as blood flow returns. Raynaud’s ranges from a mild nuisance to a genuinely disabling problem depending on its severity.
A double-blind, placebo-controlled trial tested IHN (sold under the brand name Hexopal) in people with primary Raynaud’s disease during winter months, when attacks are most frequent and severe. The IHN group reported feeling subjectively better and experienced shorter and fewer episodes of vasospasm compared to the placebo group.6PubMed. A double blind randomised placebo controlled trial of hexopal in primary Raynaud’s disease The researchers noted that the mechanism behind the benefit was unclear but that the compound was safe and effective for reducing attacks.
This is worth lingering on because it suggests IHN may have vascular effects that operate differently from the classic niacin-flush pathway. Niacin itself is a vasodilator, meaning it relaxes blood vessel walls, and it is plausible that even modest, sustained levels of free niacin could help counteract the exaggerated vasoconstriction that characterizes Raynaud’s. You do not necessarily need the high peak concentrations that shift liver lipid metabolism to relax peripheral vessels enough to reduce spasm frequency. The therapeutic bar is simply lower for that application.
IHN was also historically investigated for intermittent claudication, a cramping pain in the legs caused by reduced blood flow during walking. The evidence there is thinner and less consistent, and modern treatment guidelines for claudication have moved toward other interventions. But the Raynaud’s data remains one area where IHN has genuinely earned clinical credibility.
How IHN Compares to Other Forms of Niacin
If you are looking at niacin supplements, you will encounter at least three main forms, and the differences between them matter more than supplement marketing typically lets on.
- Immediate-release niacin (nicotinic acid): This is plain, unmodified niacin. It causes the most flushing, particularly at higher doses, but it also delivers the strongest and most well-documented effects on cholesterol. Prescription-grade immediate-release niacin has decades of clinical trial data behind it.
- Extended-release niacin: This uses a wax matrix or other slow-release formulation to spread absorption over several hours. It reduces flushing compared to immediate-release, though it does not eliminate it entirely. It preserves most of the lipid-modifying effect and is the form typically prescribed by doctors. It does carry a slightly higher risk of liver toxicity than immediate-release niacin, particularly at higher doses.
- Inositol hexanicotinate: The flush-free option. It is the gentlest on side effects but, based on the available comparison data, the weakest at moving cholesterol numbers. It is sold as a dietary supplement rather than a prescription drug in most countries.
There is a fourth compound that often gets confused with these: nicotinamide (also called niacinamide). Nicotinamide is another form of vitamin B3 and does not cause flushing, but it also has no meaningful effect on cholesterol. Its biological role overlaps with niacin in terms of meeting the body’s basic vitamin B3 needs, but the two differ sharply in their pharmacological effects at higher doses. IHN is sometimes confused with nicotinamide-based “flush-free” products, but they are chemically and functionally different.
The practical takeaway is that the “flush-free” label on IHN supplements is accurate but potentially misleading. If you are taking niacin specifically for cardiovascular lipid management, avoidance of flushing and avoidance of lipid effects may turn out to be the same thing. The flush and the cholesterol benefits appear to share a dependence on achieving a certain threshold concentration of free niacin in the blood, and IHN’s slow-release design may keep levels below that threshold for both.
Safety and Tolerability
One area where IHN performs well is safety. Because it avoids the high peak niacin concentrations that cause both flushing and liver stress, IHN supplements are generally well tolerated at typical doses. The comparison trial that found IHN no better than placebo for cholesterol also reported that IHN was well tolerated throughout the study period.4Journal of Clinical Lipidology. Wax-matrix extended-release niacin vs inositol hexanicotinate: A comparison of wax-matrix, extended-release niacin to inositol hexanicotinate “no-flush” niacin in persons with mild to moderate dyslipidemia Liver enzyme elevations, a known concern with high-dose niacin therapy, have not been flagged as a significant issue with IHN in published trials.
This safety profile is one reason IHN remains popular as an over-the-counter supplement despite its weak cholesterol data. For people who want niacin’s general nutritional benefits without risking unpleasant side effects, IHN provides niacin in a tolerable form. It does release niacin, just not in the pharmacological surge needed for lipid management. As a source of vitamin B3 to meet daily nutritional requirements, it works fine.
That said, the supplement market can be a confusing place. IHN products are often sold alongside bold claims about cardiovascular health, sometimes citing older European research on peripheral circulation or cherry-picking favorable endpoints from small studies. If a product promises flush-free cholesterol support, the strongest available comparison study suggests you should be skeptical of that particular pairing of benefits.
The Inositol Component
When IHN breaks down, it releases not only niacin but also free inositol, the sugar alcohol at its core. Inositol itself is a biologically active molecule that has attracted its own research attention in recent years. It plays roles in cellular signaling, insulin sensitivity, and mood regulation. Some studies have investigated myo-inositol (the most common form of inositol in the body) for conditions like polycystic ovary syndrome and anxiety, with varying levels of evidence.
Whether the amount of inositol released from a typical IHN supplement dose is large enough to produce any of these effects is unclear. A standard IHN supplement providing the equivalent of 500 milligrams of niacin would release a proportionally smaller amount of inositol, since the inositol molecule is outnumbered six-to-one by the niacin units in the compound. People taking inositol for its own therapeutic purposes typically use much higher standalone doses. So while the inositol contribution from IHN is real, it is unlikely to be pharmacologically meaningful for conditions where inositol supplementation is specifically studied.
Why the Research Landscape Is Thin
One frustration for anyone trying to make an informed decision about IHN is how little modern clinical research exists. Most of the peripheral vascular studies date from the 1980s, and the head-to-head cholesterol comparison that found IHN equivalent to placebo, while well-designed, is a single study. The positive HDL finding comes from a conference abstract rather than a full peer-reviewed publication, which means it has not undergone the same level of scrutiny.
Part of the reason is economic. IHN is not patentable as a novel drug, so there is little financial incentive for pharmaceutical companies to fund large-scale trials. It exists in a regulatory gray zone as a dietary supplement in most markets, which means it does not need to prove efficacy to be sold. The European Food Safety Authority has evaluated it as a source of niacin for nutritional purposes, but that is a different question from whether it works as a lipid-lowering agent.
The result is that consumers and clinicians are left making decisions based on limited and sometimes contradictory evidence. IHN is not harmful, it does deliver niacin, and it does avoid flushing. But the gap between “safe and well tolerated” and “clinically effective for the condition you care about” is wide, and IHN sits squarely in that gap for most cardiovascular applications. For Raynaud’s disease and peripheral circulation, the evidence is more encouraging but still sparse by modern standards. Anyone considering IHN as a therapeutic supplement rather than a basic nutritional source should weigh that uncertainty honestly, ideally with input from a doctor who can review their specific lipid panel and health goals.